Polen Capital, an investment management company, released its “Polen Global Growth Strategy” third-quarter 2024 investor ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But ...

Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, ...

Novo Nordisk has announced the continuation of its ambitious 2024 share repurchase program, now initiating an additional buyback of up to DKK 3.14 billion. This move aims to reduce the company’s share ...

Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex ...

Benefits shown in review of 10,000 patients, Hims says Novo and Lilly have raised questions about copycat medicines Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a ...

A former regional account manager working for Novo Nordisk Inc. is suing the healthcare company, alleging it failed to accommodate her disabilities, retaliated against her, and wrongfully terminated ...

The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has promoted its weight loss medications semaglutide (Ozempic/Wegovy) and ...